Vaishali Pharma's Q3 FY24 marked by a remarkable 37.59% increase in revenue
India, Feb. 7 -- PNN
Mumbai (Maharashtra) [India], February 7: Vaishali Pharma Limited (NSE - VAISHALI), engaged in production and marketing of a diverse range of pharmaceutical products, announced its unaudited Financial Results for Q3 & 9M FY24.
Key Financials at a Glance:
Q3 FY24
- Total Income at Rs 28.37 Cr
- EBITDA at Rs 3.42 Cr
- EBITDA Margin at 12.05%
- Net Profit at Rs 2.11 Cr
- NPM (%) at 7.44%
- EPS at Rs 1.99
9M FY24
- Total Income at Rs 55.01 Cr
- EBITDA at Rs 9.05 Cr
- EBITDA Margin at 16.45%
- Net Profit at Rs 5.4 Cr
- NPM (%) at 9.82%
- EPS at Rs 5.10
Commenting on the performance, Atul Vasani, Chairman and Managing Director of Vaishali Pharma Limited said, "We are delighted to share our Q3 FY24 results, ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.